WebDoctor Encyclopedia

Childhood Chronic myeloid & MDS

Juvenile myelomonocytic leukaemia (JMML)

Juvenile myelomonocytic leukaemia (JMML) is a rare leukaemia of babies and young children caused by changes in the RAS signalling pathway. Most children need a stem cell transplant, though a few mild forms settle by themselves.

Medically reviewed Last reviewed November 15, 2026

What is juvenile myelomonocytic leukaemia?

Juvenile myelomonocytic leukaemia (JMML) is a rare blood cancer of babies and young children. Most children are diagnosed before the age of 6, and the average age is about 2.

In JMML, the bone marrow makes too many monocytes and other immature white blood cells called myeloid cells. These cells crowd the marrow and spread into the spleen, liver, skin, lungs and gut.

JMML is unusual because it has features of two groups of blood disorders. It causes the overgrowth seen in myeloproliferative neoplasms and the faulty blood cell production seen in myelodysplastic syndromes.

Almost every case is driven by a change in genes of the RAS signalling pathway, which controls how cells grow and divide. Some of these gene changes are inherited as part of conditions such as neurofibromatosis type 1 or Noonan syndrome.

JMML is serious. For most children, a stem cell (bone marrow) transplant offers the only chance of cure.

A small group of children, especially those with certain inherited CBL or some NRAS changes, have a milder form that may settle without transplant.

1. Key facts at a glance

Feature Details
Type of disease Childhood myeloproliferative/myelodysplastic neoplasm
How common About 1-2 children per million each year; 1-2% of childhood leukaemias
Typical age Median about 2 years; most under 6
Sex Boys about twice as often as girls
Main cause Changes in RAS pathway genes in about 90%
Linked conditions Neurofibromatosis type 1, Noonan syndrome, CBL syndrome
Main treatment Allogeneic stem cell transplant; azacitidine before transplant
Outlook About 50-60% cured with transplant

2. Causes and genetics

JMML is caused by changes in genes that control the RAS pathway. When this pathway is stuck “on”, myeloid cells grow and multiply out of control.

A typical feature is that JMML cells are extremely sensitive to a growth signal called GM-CSF.

Gene How often Notes
PTPN11 About 35% Usually acquired in the leukaemia only; inherited changes cause Noonan syndrome (Kratz et al., 2005)
NRAS About 15-20% Acquired; a few cases are mild
KRAS About 15% Acquired; often younger children, sometimes with monosomy 7
NF1 About 10-15% Usually in children with neurofibromatosis type 1
CBL About 10-15% Often inherited; many cases resolve without transplant (Niemeyer et al., 2010)
No RAS pathway change Under 10% Other rare gene changes

About a quarter of children also have monosomy 7, which means one copy of chromosome 7 is missing from the leukaemia cells.

Doctors are increasingly using DNA methylation testing, a measure of chemical tags on the DNA, to sort children into low, intermediate and high-risk groups (Schonung et al., 2021).

Noonan syndrome and JMML

Babies with Noonan syndrome can develop a JMML-like condition in the first weeks of life. This is called Noonan syndrome-associated myeloproliferative disorder. It usually settles on its own within months, although a few children need treatment.

3. How does it look

Visible signs in the child

Children with JMML often look unwell, pale and tired. Parents commonly notice a swollen tummy caused by an enlarged spleen and liver.

Visible sign Description
Swollen abdomen An enlarged spleen is found in almost every child; the liver is often enlarged too
Paleness From anaemia
Bruises and small red spots Bruising easily and pinpoint red spots (petechiae) from low platelets
Skin rash Red, scaly or eczema-like rash, often on the face; affects about 40-50%
Yellowish skin bumps Small fatty deposits (xanthomas), especially in children with NF1
Cafe-au-lait spots Light brown patches on the skin in children with NF1
Swollen glands Enlarged lymph nodes in the neck and elsewhere
Noonan features Wide-set eyes, low-set ears, short neck and heart problems in children with Noonan syndrome

Blood tests and the microscope

A blood film shows a high white cell count with many monocytes. Immature myeloid cells and nucleated red blood cells may also be present.

Platelets are usually low. The level of foetal haemoglobin (HbF), a type of haemoglobin normally made before birth, is often raised for the child’s age.

Bone marrow is usually packed with cells, but the proportion of very immature cells (blasts) stays below 20%. If blasts are 20% or more, the disease has become acute myeloid leukaemia.

4. Symptoms

Symptoms usually develop over weeks to months. They are often mistaken at first for common childhood infections.

Common symptoms

  • Paleness, tiredness and irritability
  • Fever, often without an obvious infection
  • Repeated infections, such as chest or ear infections
  • Swollen tummy from a large spleen and liver, which can make feeding uncomfortable
  • Poor feeding, vomiting and failure to gain weight
  • Bruising, nosebleeds or bleeding gums
  • Skin rashes
  • Cough and fast breathing from leukaemia cells in the lungs
  • Diarrhoea, sometimes with blood, from leukaemia cells in the gut
  • Swollen glands in the neck

When to seek medical advice

Take your child to a doctor if they are persistently pale, have a swollen tummy, unexplained bruising or fevers that keep returning. A simple full blood count is the first step.

Children with NF1 or Noonan syndrome who develop these symptoms should be checked promptly.

5. Diagnosis

Diagnosis follows criteria from the World Health Organization (Khoury et al., 2022) and the International Consensus Classification (Rudelius et al., 2023).

Core features

All of the following are needed:

  • Monocytes of 1 x 10^9/L or more in the blood
  • Blasts below 20% in blood and bone marrow
  • Enlarged spleen
  • No BCR::ABL1 fusion, which would point to chronic myeloid leukaemia instead

Supporting features

Supporting finding Notes
RAS pathway gene change PTPN11, NRAS, KRAS, NF1 or CBL; confirms the diagnosis in most children
Clinical NF1 Diagnosis of neurofibromatosis type 1
Monosomy 7 Or other chromosome changes
Raised HbF Higher than normal for age
Immature cells in the blood Myeloid or red cell precursors
High white cell count Over 10 x 10^9/L
GM-CSF hypersensitivity Specialist laboratory test

Tests used

Test Purpose
Full blood count and blood film Look for monocytes, low platelets and immature cells
Bone marrow test Check blasts and chromosome changes
Gene tests on blood or marrow Find RAS pathway changes
Germline testing On skin or hair cells to check for inherited changes (CBL, PTPN11, NF1)
HbF level Supports the diagnosis and helps predict outlook
Ultrasound Measures spleen and liver size
Chest X-ray or CT Checks for lung involvement

Doctors must also rule out infections that can mimic JMML, such as cytomegalovirus, Epstein-Barr virus and other viruses.

How JMML differs from other childhood leukaemias

Feature JMML Acute lymphoblastic leukaemia (ALL) Acute myeloid leukaemia (AML)
Typical age Under 6, median about 2 Peak at 2-5 years Infants and teenagers
Blasts in marrow Below 20% 20% or more (usually much higher) 20% or more
Main cells increased Monocytes and myeloid cells Lymphoblasts Myeloblasts
Spleen Almost always enlarged Sometimes enlarged Sometimes enlarged
Response to standard chemotherapy Poor Good Moderate
Main curative treatment Stem cell transplant Chemotherapy Chemotherapy, sometimes transplant

6. Risk factors for a poorer outlook

Factor Effect
Age over 2 years at diagnosis Higher risk
Platelets below 33 x 10^9/L Higher risk
High HbF for age Higher risk
High-methylation group Higher risk of relapse
PTPN11 or NF1 changes Usually aggressive; transplant needed
Inherited CBL change Often a milder course; may resolve

7. Treatment

Treatment is given in specialist children’s cancer centres, usually within international study groups such as EWOG-MDS (Niemeyer and Flotho, 2019).

Stem cell transplant

An allogeneic haematopoietic stem cell transplant is the main treatment and the only proven cure for most children. Healthy blood-forming cells come from a matched brother or sister, an unrelated donor or umbilical cord blood.

In a large European study, about half of children were cured with transplant. Relapse of the leukaemia was the main cause of failure (Locatelli et al., 2005).

What a transplant involves

Before the transplant, the child receives high-dose chemotherapy (conditioning), usually a combination of busulfan, cyclophosphamide and melphalan. This clears the bone marrow and the leukaemia cells.

The donor cells are then given through a drip, like a blood transfusion. They travel to the bone marrow and start making new blood cells over two to four weeks.

During this time the child is very vulnerable to infection and stays in a protective isolation room. The main risks after transplant are infections, graft-versus-host disease (when donor immune cells attack the child’s body) and relapse.

Interestingly, donor immune cells also help to fight remaining leukaemia cells. Doctors may therefore reduce immune-suppressing medicines quickly if signs of relapse appear.

Treatment before transplant

Treatment Purpose
Azacitidine A gentle drug given by injection; shrinks the disease in many children before transplant (Cseh et al., 2015; Niemeyer et al., 2021)
Low-dose chemotherapy Mercaptopurine or cytarabine to control a high white count
Splenectomy Removal of a very large spleen in selected children
Supportive care Blood and platelet transfusions, antibiotics and nutrition

Azacitidine is approved in the United States for newly diagnosed JMML.

Watch and wait

Children with inherited CBL changes, Noonan-associated disease and some NRAS-mutated cases may be closely monitored without transplant, as their disease can settle by itself.

New treatments

MEK inhibitors such as trametinib, which block the RAS pathway, are being studied in clinical trials for relapsed or high-risk JMML.

Relapse after transplant

Relapse usually happens within the first year. Options include a second transplant, which cures about a third of these children, and infusions of donor immune cells.

8. Outlook (prognosis)

Situation Typical outlook
After stem cell transplant About 50-60% long-term survival without relapse
Inherited CBL or Noonan-associated disease Often resolves without transplant
Some NRAS-mutated, low-methylation cases May have a mild course
Aggressive disease without transplant Usually fatal within a few years

Children who are cured are followed for many years. Late effects of transplant can include growth problems, hormone changes, fertility problems and effects on the heart and lungs.

After transplant, doctors check the blood regularly for chimerism, which measures what proportion of blood cells come from the donor. A falling donor proportion can be an early warning of relapse, allowing treatment to start before symptoms return.

Gene tests for the child’s specific RAS pathway change can also be used to look for very small amounts of remaining leukaemia.

9. Living with JMML

A diagnosis of JMML is overwhelming for families. Treatment can last many months, with long hospital stays around transplant time.

Need Support available
Information Your child’s specialist team and nurse specialist
Emotional support Psychologists, social workers and play specialists
Practical help Charities offering accommodation, travel and financial support
Genetic questions Genetic counselling if an inherited change is found
Long-term follow-up Late effects clinics after transplant

10. Frequently asked questions

Question Answer
Did we cause our child’s JMML? No. Nothing parents did or did not do causes JMML
Is it inherited? Usually not, but some cases are linked with NF1, Noonan syndrome or inherited CBL changes
Will brothers and sisters be affected? Very rarely; genetic testing can clarify the risk if an inherited change is found
Does every child need a transplant? Most do, but some children with CBL, Noonan-related or mild NRAS disease may not
Can JMML come back after transplant? Yes, in about a third of children, usually within a year

11. Questions to ask your child’s care team

  • What gene change does my child’s JMML have?
  • What is my child’s risk group?
  • Does my child need a transplant, and is there a suitable donor?
  • Will my child receive azacitidine or other treatment first?
  • Should our family have genetic testing?
  • What long-term effects should we watch for?

Resources

  1. Locatelli, F. et al. (2005) ‘Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial’, Blood, 105(1), pp. 410-419.
  2. Niemeyer, C.M. and Flotho, C. (2019) ‘Juvenile myelomonocytic leukemia: who’s the driver at the wheel?’, Blood, 133(10), pp. 1060-1070.
  3. Niemeyer, C.M. et al. (2010) ‘Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia’, Nature Genetics, 42(9), pp. 794-800.
  4. Niemeyer, C.M. et al. (2021) ‘Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial’, Blood Advances, 5(14), pp. 2901-2908.
  5. Cseh, A. et al. (2015) ‘Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group’, Blood, 125(14), pp. 2311-2313.
  6. Schonung, M. et al. (2021) ‘International consensus definition of DNA methylation subgroups in juvenile myelomonocytic leukemia’, Clinical Cancer Research, 27(1), pp. 158-168.
  7. Kratz, C.P. et al. (2005) ‘The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease’, Blood, 106(6), pp. 2183-2185.
  8. Khoury, J.D. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms’, Leukemia, 36(7), pp. 1703-1719.
  9. Rudelius, M. et al. (2023) ‘The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia’, Virchows Archiv, 482(1), pp. 113-130.
  10. National Cancer Institute (2026) Childhood Myeloproliferative Neoplasms Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/myeloproliferative/hp/child-mpn-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.